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Abstract Autophagy is an essential cellular pathway by
which protein aggregates, long-lived proteins, or defective
organelles are sequestered in double membrane vesicles and
then degraded upon fusion of those vesicles with lysosomes.
Although autophagy plays a critical role in maintaining intra-
cellular homeostasis and keeping the cell in a healthy state,
this key pathway can become dysregulated in various cardio-
metabolic disorders, such as; obesity, dyslipidemia, inflam-
mation, and insulin resistance. In these conditions, autophagy
may actually worsen the pathological state instead of
protecting the cell or organism. In this review, we discuss
how dysregulated autophagy may be linked to increases in
cardiovascular risk factors, and how manipulation of the au-
tophagic machinery might reduce those risks.
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1 Introduction
A detailed understanding of how cells maintain homeostasis
through the balance of the synthesis and breakdown of proteins
is critical to the development of new strategies to prevent and/or
treat human disease states. Autophagy, or self-eating, is a general
term for the catabolic processes, conserved from yeast to
humans, that involves lysosomal degradation of cell constituents
(including mitochondria, peroxisomes, and endoplasmic reticu-
lum), unfolded or misfolded proteins, and intracellular patho-
gens. Autophagy can be induced by a change in cellular envi-
ronment or in response to starvation when a rapid recycling of
fatty acids and amino acids is required to ensure cell survival [1].
Association studies have found a link between autophagy and
cardiovascular disease [2–4]; and recently, several publications
have reported a strong relationship between autophagy and
cardiometabolic risk factors such as obesity [5–7], dyslipidemia
[8–10], inflammation [11–13], insulin resistance, and diabetes
mellitus [14–16]. The objective of the present review is to
describe how dysregulation of autophagy in these states can
increase cardiovascular risk, and how manipulation of the au-
tophagic machinery may reverse the disordered metabolism
driving these risk factors.
2 Autophagy
When first described in 1966, autophagy was considered a non-
selective process; however, the findings that different cytosolic
proteins are degraded by lysosomes at different rates, and that
some organelles or proteins are preferentially degraded under
particular conditions, indicate a level of selectivity in lysosome-
dependent degradation [17]. Although constitutive mammalian
autophagy is essential for basal cellular metabolism and ho-
meostasis, increased levels of lysosomal degradation of cell
components have been found under conditions of nutrient or
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oxygen deprivation, endoplasmic reticulum stress, proteasome
malfunction, or damage caused by environment changes [2,
18].
There are three types of autophagy in the cell:
macroautophagy (MAC-A), chaperone-mediated autophagy
(CMA), and microautophagy (MIC-A). MAC-A is a process in
which components of the cytoplasm, including long-lived pro-
teins and organelles, are sequestered inside double-membrane
vesicles called autophagosomes. The autophagosomes then fuse
with lysosomes to form autophagolysosomes, where the contents
are degraded and their molecular components released for
recycling or energy production [18, 19]. CMA is driven by the
heat shock cognate (HSC) 70, which binds specific polypeptides
or proteins containing a KFERQ motif and transports them
directly into the lysosome, where interaction with the
lysosome-associated membrane protein (LAMP) type 2A recep-
tors leads to protein internalization and degradation [20, 21].
Finally, in MIC-A, defective molecules or organelles are directly
engulfed into the lysosomes for degradation and recycling of
their components [22]. In this review we will focus on MAC-A.
TheMAC-A process is divided in four different mechanistic
steps: initiation, nucleation, autophagosome formation, and
fusion of the autophagosome with the lysosome resulting in
catabolism of the contents (Fig. 1). These processes are medi-
ated by different sets of proteins, encoded by approximately 30
autophagy-related genes (ATGs) characterized in yeast, but
highly conserved in eukaryotes cells [4, 18].
2.1 Initiation
The exact source of the lipids and/or membranes for the initial
phagophore is currently unknown and being debated. Some
researchers have reported that during initiation, recruitment of
lipids from several organelles, depending on the cell type and
stimulus, results in the formation of isolation membranes [18].
The initiation step is controlled by a complex of the uncoor-
dinated 51-like kinase 1 (ULK1, also called Atg1), Atg13, and
focal adhesion kinase interacting protein of 200 kD (also
called Atg17). It is suggested that mammalian Atg13 and
Atg17 are phosphorylated by ULK1 [23], and that ULK1 also
undergoes autophosphorylation, which is conducive to a con-
formational change and autophagy induction [24]. Some stud-
ies have suggested that Atg13 is phosphorylated by either the
mammalian target of rapamycin (mTOR) or ULKs on differ-
ent residues, which may exert opposite effects on autophagy
induction dependent on nutrient status [4]. The mammalian
target of rapamycin complex 1 (mTORC1) is an important
component of a network that senses the nutrient state of the
cell and accordingly controls the levels of anabolism and
catabolism to maintain homeostasis [25]. Low glucose levels
or high levels of adenosine 5’-monophosphate (AMP), which
indicates low cellular energy status, nutrient deprivation, or
stress, activate AMP-activated protein kinase, which in turn
inhibits mTORC1 activity and induces its dissociation from
the ULK1-Atg13-Atg17 complex. As a result, ULK1 is enzy-
matically active and phosphorylates Atg13 and Atg17 to
stimulate the MAC-A process [25, 26]. In contrast, under
normal physiological conditions, insulin and insulin like
growth factor 1 indirectly induce mTORC1 activity and in-
hibit autophagy by stimulating class 1 phosphoinositol 3-
kinase (PI3K) production of phosphatidylinositol 3-
phosphate (PI3P), which induces the Akt kinase at the plasma
membrane, and promotes mTORC1 activity [27, 28]. High
levels of amino acids also increase mTORC1 activity, by
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Fig. 1 Schematic illustration of autophagy
enhancing binding of this complex to regulatory proteins Rag
and Rheb (Ras homolog enriched in brain) guanosine
triphosphatases [29, 30].
2.2 Nucleation
This step requires a class III PI3K called vacuolar protein
sorting 34 (Vps34) that forms a complex with Beclin 1 (also
called Atg6/Vp330), p150 (also called Vps15) and Atg14L
[31]. Production of PI3P by the Vps34 complex recruits WIPI
(WD40 repeat protein interacting with phospho-inositides/
Atg18) to the isolation membrane, allowing recruitment of
the light chain of the microtubule-associated protein 1 (LC3I/
Atg8) and further maturation of the autophagosome [32].
While specific inhibition of class I PI3K stimulates MAC-A
indirectly through downstreamAkt/mTOR inhibition, specific
inhibition of Vps34 inhibits MAC-A through reduction of an
autophagy-specific PI3P pool [33]. The function of Beclin 1 in
autophagy has been shown to be regulated by B-cell lympho-
ma/leukemia-2, an anti-apoptotic protein that inhibits autoph-
agy by binding and sequestering Beclin 1 under nutrient-rich
conditions [4]. There are also other mTOR-independent au-
tophagy pathways like c-Jun NH2-terminal kinase 1, which
may induce autophagy by phosphorylating B-cell lymphoma/
leukemia-2 or Bim (a proapoptotic molecule which inhibits
autophagy by its interaction with Beclin 1) and abolishing
their inhibitory effects on autophagy [34].
2.3 Autophagosome formation
This step is mediated by two interdependent ubiquitin-like
conjugation pathways. In one, Atg12 is activated by Atg7
(E1 activating enzyme) and attached to an internal lysine of
the substrate protein Atg5 covalently. Atg12–Atg5 conjuga-
tion is constitutive and irreversible and further interacts with a
coiled-coil protein Atg16, which allows the Atg12–Atg5–
Atg16 complex to become a te t ramer by se l f -
oligomerization and also attaches it to the phagophore [4,
33]. The phagophore is an initial sequestering compartment,
essential in regulating the membrane elongation and expan-
sion that is essential for autophagosome formation. In the
second pathway, LC3I is first cleaved by the Atg4 serine
protease and then conjugated to phosphatidylethanolamine
by Atg7 and Atg3 (E1 and E2 enzymes, respectively),
allowing LC3I to engage the Atg12–Atg5–Atg16 complex
on the phagophore. Once fixed to that complex, LC3I is
lipidated to form LC3II. The two forms can be distinguished
by Western blot analysis. After the autophagosome isolation
membrane is formed, the Atg12–Atg5–Atg16 complex is
released, whereas LC3II remains associated with the
autophagosome until its fusion with the lysosome. In
nutrient-rich conditions, the majority of LC3 is cytosolic;
upon autophagy induction, LC3 largely exists as LC3II and
is localized to both sides of the phagophore [35, 36].
2.4 Vesicle fusion and autophagosome breakdown
The autophagosomes-lysosomes fusion step is mediated by
dynein-mediated transport of the autophagosomes along mi-
crotubules to fuse with endosomes or lysosomes. When
autophagosome formation is completed, LC3II attached to
the outer membrane is cleaved from phosphatidylethanol-
amine by Atg4 and released back to the cytosol [37]. In
mammalian cells, the fusion event requires the LAMP type
2A receptor and the small GTPase, Rab7 [38, 39]; however,
the exact mechanism remains to be demonstrated. After
autophagosome and lysosome fusion, degradation of the inner
vesicle is dependent on a series of lysosomal/vacuolar acid
hydrolases, such as proteinases A and B (encoded by PEP4
and PRB1, respectively) and cathepsins B, D and L [40]. The
resulting small molecules generated from this degradation,
particularly amino acids, are released back to the cytosol for
re-utilization in protein synthesis and maintenance of cellular
functions. The tricarboxylic acid cycle, which utilizes amino
acids for generation of bioenergetic molecules and biosynthet-
ic intermediates, appears to co-ordinate with MAC-A through
negative feedback of pyruvate on MAC-A [4]. Lipid break-
down supplies free fatty acids needed to sustain cellular rates
of mitochondrial β-oxidation and adenosine-5’-triphosphate
generation, maintain cellular homeostasis, and promote the
metabolism of potentially toxic lipid molecules [10].
3 Obesity and autophagy
Increasing rates of overweight and obesity worldwide are
closely linked to incidence of metabolic disorders worldwide.
Both conditions are associated with accumulation of adipose
tissue. White adipose tissue (WAT) functions to store energy
in the fed state by taking up free fatty acids and synthesizing
TG, which can later be hydrolyzed to provide fatty acids to
other tissues during fasting or exercise. In contrast, brown
adipose tissue (BAT) has a reduced capacity for lipid storage,
but a high rate of β-oxidation that is mediated by the mito-
chondrial uncoupling protein [10, 41]. Previous reports in
cellular and animal models have shown that general obesity
and metabolic disease correlate with decreased BAT activity,
whereas resistance to metabolic disease from obesity corre-
lates with increased BAT function or the induction of brown
adipocyte-like gene expression in WAT [9, 10].
Autophagy has been implicated in cellular development and
differentiation including adipogenesis. In a recent study, by
Singh and colleagues [5], inhibition of autophagy with 3-
methyladenine or knockdown of Atg7 in 3T3-L1 pre-
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adipocytes reduced accumulation of TG and expression of
transcription factors such as peroxisome proliferator-activated
receptor gamma and CCAAT-enhancer-binding protein, which
are involved in adipocyte differentiation. Inhibition of autoph-
agy was also associated with decreased markers of differentiat-
ed adipocytes, such as fatty acid synthase, stearoyl-coenzymeA
desaturase 1, and glucose transporter 4. Consistent with these
findings, studies in Atg5-null murine embryonic fibroblasts
showed a decrease in adipocyte differentiation and lipid accu-
mulation [42]. Additionally, mice with targeted knockout of
Atg7 in adipose tissue have decreasedWATmass and increased
mitochondrial uncoupling protein and mitochondrial enzymes,
leading to a ~32 fold higher β-oxidation in adipose tissue,
which suggests that the decrease in lipid storage was secondary
to a failure in differentiation and not a direct effect on lipid
metabolism [5]. The transformation of WAT from an energy-
storing tissue into an energy-expending tissue resulted in a
leaner mouse that was resistant to high fat diet-induced obesity,
had lower plasma concentrations of free fatty acids, triglycer-
ides and cholesterol, and showed a markedly increased sensi-
tivity to insulin [5, 10]. In line with these results, human studies
revealed that autophagy is upregulated in obese individuals,
who have increased expression of autophagy-related proteins
Atg5, LC3I and LC3II, as well as elevated autophagic flux in
both omental and subcutaneous adipose tissue [6, 7]. These
results suggest that blocking autophagy in adipose tissue might
lead to reduced WAT and increased BAT or beige/browned
WAT with greater β-oxidation. Such a change in the balance
of WAT and BAT would decrease obesity and some of the
associated metabolic disorders [43].
4 Lipoprotein metabolism and autophagy
Abnormalities in lipoprotein metabolism leading to
dyslipidemias are important in atherogenesis and the develop-
ment of clinical cardiovascular disease. Lipoproteins are mac-
romolecular spherical complexes of lipids and proteins that
carry hydrophobic neutral lipids such as cholesterol esters and
triglycerides in a core surrounded by amphipathic phospho-
lipids, free cholesterol, and apolipoproteins. The structure of
the lipoprotein allows the hydrophobic core lipids to traverse
the hydrophilic environment of plasma. Lipoproteins can be
classified according to their hydrated density into chylomicrons,
very-low-density-lipoproteins (VLDL), intermediate-density li-
poproteins (IDL), low-density lipoproteins (LDL) and high
density lipoproteins (HDL) [44, 45]. The role of VLDL (syn-
thesized in liver) and chylomicrons (synthesized in intestine) is
to deliver energy, in the form of triglycerides, to peripheral
tissues using lipoprotein lipase to generate free fatty acids. After
release of fatty acids, the remnants of VLDL and chylomicrons
return to the liver where they are taken up to deliver their
remaining triglycerides and most of their cholesterol; varying
proportions of VLDL remnants and nearly all chylomicron
remnants are removed by the liver. Remnant lipoprotein choles-
terol plays a key role in the regulation of hepatic cholesterol
homeostasis, including regulation of cholesterol synthesis and
LDL receptor expression. The VLDL that is not removed by the
liver is converted to LDL after passing through the IDL state.
VLDL, chylomicron remnants, IDL and LDL, which all carry
apolipoprotein B, are each atherogenic because they can perme-
ate the endothelial layer of arteries and initiate and/or increase
atherosclerotic plaque formation [10, 45].
Apolipoprotein B100 (apoB100) is a protein synthesized in
liver that is essential to the formation of VLDL, IDL and LDL.
Considering the critical role that apoB100 plays in lipid trans-
port, metabolic regulation, and atherogenesis, it is not surpris-
ing that regulation of apoB100 itself, or apoB100-containing
lipoproteins, is complex and occurs at several stages [45].
Multiple apoB100 degradative pathways have been described,
and dysregulation of some of these pathways may contribute
to the overproduction of VLDL concomitant with increased
plasma triglyceride and LDL levels in blood. Factors associ-
ated with such dysregulation of hepatic apoB100 metabolism
include insulin resistant states such as obesity, metabolic
syndrome, and type 2 diabetes mellitus [46, 47].
Like all secreted proteins, apoB100 is synthesized at the
surface of the endoplasmic reticulum (ER), where the protein
is lipidated during its translocation across the ER membrane by
microsomal triglyceride transfer protein (MTP) (Fig. 2). This
lipidation allows apoB100 to complete translocation and initiate
the assembly of VLDL. In lipid-poor conditions or in absence of
MTP, a large proportion of newly synthesized apoB100 is co-
translationally ubiquitinylated and degraded by the proteasome.
However, some experimental models have shown that approx-
imately 50 % or more apoB100 degradation occurs after trans-
location, and this is mainly non-proteosomal degradation [45,
48]. The co-localization of proteosomes, autophagosomes, and
apoB100 in structures resembling LDs has suggested the in-
volvement of autophagic mechanisms in apoB100 degradation
[49]. Furthermore, when the concentration of misfolded proteins
rises in the ER, the unfolded protein response is triggered,
leading to increased synthesis of ER chaperones and activation
of other degradation pathways, including autophagy [45, 50].
Other studies have shown that increased delivery of omega-3
poly-unsaturated fatty acids induce autophagicapoB100 degra-
dation, reducing the secretion of VLDL [51, 52]. The induction
of this degradation most likely occurs in the Golgi (post-ER
presecretory proteolysis), where the VLDL-apoB100 undergoes
aggregation after exposure to lipid peroxides. In contrast to
proteosomal degradation, post-ER presecretory proteolysis can
occur even when lipid availability and MTP are normal. These
data suggest a potential therapeutic role for autophagy in states
of increased VLDL secretion and hyperlipidemia. Previous
studies have shown that HDL are lipoproteins with antioxidant,
anti-apoptotic, and anti-inflammatory properties. A recent study
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indicated that HDL may also prevent the expression of LC3II
and Beclin 1 in human endothelial cells, thereby preventing the
autophagy triggered by oxidized LDL [53].
The fact than during fed state, both autophagy and lipolysis are
suppressed (leading to cellular lipid storage for future energy
demands), and that during periods of limited nutrient supply
autophagy increases in parallel with lipolysis, suggest a potential
interrelationship between these two pathways. In this respect, very
interesting in vitro and in vivo experiments indicate that inhibition
of MAC-A by 3-methyladenine or knockdown of Atg5 or Atg7
genes significantly increased hepatic triglycerides and cholesterol
content in mice during prolonged fasting, when delivery of fatty
acids to the liver was dramatically increased [7]. The increased
hepatic lipid content was present in lipid droplets (LDs), which
are cytosolic structures where lipids are stored as a central core of
triglycerides and cholesterol esters surrounded by a phospholipid
monolayer and associated proteins [54]. Prolonged fasting was
also associated with: 1) decreased rates of lipolysis and fatty acid
β-oxidation; 2) movement of lipids through the autophagic path-
way, indicated by colocalization of neutral lipids with markers of
autophagic vacuoles and lysosomes, and by findings of LDs
within autophagic vacuoles; and 3) direct interaction of LC3 with
LDs before autophagosome formation [7]. These results indicate
that autophagy may play a role in the regulation of hepatocyte
lipid content, through breakdown of LDs stored triglycerides and
cholesterol, by a pathway the authors called lipophagy [9, 10].
This alternative pathway for lipid metabolism may provide hepa-
tocytes with the ability to mobilize large amount of bulk lipids for
oxidation when other sources of energy are very limited. These
results also suggest that activation of autophagy/lipophagy might
be an approach to reducing hepatic steatosis.
5 Inflammation, atherosclerosis and autophagy
Inflammation is the first response of the immune system to
infection or tissue injury. Although the initial inflammatory
response is beneficial, prolonged or chronic inflammation is
detrimental, playing a role in diseases such as atherosclerosis
[55]. Atherosclerotic lesions begin with dysregulated lipid
metabolism resulting in lipoproteins infiltrating the vessel
wall, followed by macrophages, leading to the development
(a) Normal assembly and secreon of apoB100/VLDL (b) Increased TG synthesis and mild endoplasmic reculum (ER) stress 
(c) Severe ER stress with steatosis (d) Smulaon of autophagy and less steatosis
Fig. 2 Forces regulating the assembly and secretion of apoB100/VLDL.
ApoB100/VLDL is a vehicle for transporting energy from the liver to the
periphery and its assembly and secretion are extremely complex. a
Nascent lipid-poor apoB100 is either targeted for complete translocation
into the lumen of the endoplasmic reticulum (ER) for assembly into
VLDL or for co- and post-translational ER degradation. The fate of
nascent apoB is dependent on lipidation with TG via the action of
microsomal triglyceride transfer protein (MTP). The TG originates from
free fatty acids (FFA) derived from three sources: 1) lipolysis of adipose
tissue, 2) VLDL and chylomicron remnants returning to the liver, and 3)
hepatic de novo lipogenesis. The VLDL formed in this step then matures
with addition of more core lipids, principally TG. This second step is also
regulated by MTP and occurs either in the ER or in a post-ER
compartment, such as the Golgi. At this point, mature VLDL can be
secreted. bWhen TG synthesis from any source is increased, the response
is an increase in VLDL secretion. However, mild or moderate ER stress
can also result. ER stress can cause increased degradation of apoB leading
to less than maximal VLDL secretion and some steatosis. c If ER stress
becomes even more severe, degradation of apoB increases further and
VLDL secretion can fall even more, leading to significant steatosis. d
Under certain conditions, autophagy can be induced at this point and
VLDL can be diverted for post-ER/Golgi degradation. Lipophagy and ER
autophagy may also occur, resulting in increased fatty acid oxidation and
less steatosis. Thus autophagy might promote both less hepatic steatosis
and less apoB100/VLDL secretion
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of lipid-laden foam cells filled with cholesterol ester (CE)-
enrich LDs [10, 56]. Breakdown of foam cell CEs by hydro-
lases is pivotal in the cholesterol mobilization from these cells.
In this respect, it has been shown recently that lipid loading
activates autophagy in macrophages, thereby targeting LDs
for delivery to lysosomes for lipolysis. This allows cholesterol
mobilization from LDs for adenosine-5’-triphosphate binding
cassette transporter-mediated cholesterol efflux and macro-
phage reverse cholesterol transport [11]. Importantly, inhibi-
tion of macrophage lysosomes only affects cholesterol efflux
from lipid-loaded, but not normal cells, indicating a specific
role for lysosomal degradation in foam cells [11]. The authors
of this study also observed that in lipid-loaded Atg5 knockout
macrophages, cholesterol efflux was decreased, but that inhi-
bition of lysosomal acid lipase had no additional effect on
cholesterol efflux, suggesting that decreased autophagic traf-
ficking of CEs to lysosomes was the cause of the decreased
cholesterol efflux [11]. Two additional studies support these
results and showed that activated macrophage autophagy pre-
vents cellular CE accumulation [14], and promotes resistance
to foam cell formation and atherosclerosis [13].
Some in vitro studies have also shown that autophagy can
be stimulated in atherosclerotic lesions by oxidized lipids [3,
57], reactive oxygen species [58], endoplasmic reticulum
stress [59], inflammation [60], and metabolic stress [61].
Although it is possible that basal stimulation of autophagy
could be atheroprotective in macrophages, it is also possible
that autophagy becomes dysfunctional in more advanced
stages of atherosclerosis and loss of autophagic function pro-
motes atherosclerosis, in part, through activation of the
inflammasome [62]. Loss of autophagy had been associated
with induction of the inflammasome and interleukin-1β pro-
cessing in macrophages, possibly through either the loss of
autophagic suppression of reactive oxygen species accumula-
tion or reduced clearance of molecules that activate the
inflammasome [63, 64]. Finally, defective macrophage au-
tophagy has been shown to increases lesion and necrotic area
in late atherosclerotic plaques, due to defective efferocytosis
of apoptotic plaque macrophages [65]. Autophagy has an
important role in the processing of efferocytosed material
and has been highlighted as a key mechanism to induce nitric
oxide production and reduce reactive oxygen species accumu-
lations [66], which are both also closely related to
atherogenesis.
6 Insulin resistance/diabetes mellitus and autophagy
Insulin is the major anabolic hormones produced by the
pancreatic β cells, and is essential for growth, development,
and homeostasis of glucose, fat, and protein metabolism.
Binding of insulin to its transmembrane receptor stimulates
the intrinsic tyrosine kinase activity of the receptor, which
phosphorylates target proteins, such as insulin receptor sub-
strates 1 to 4, to trigger two major kinase cascades, the PI3K
and the mitogen-activated protein kinase pathways, that me-
diate the metabolic and growth-promoting functions of insu-
lin, respectively [67, 68]. Individuals with insulin resistance
have increased plasma insulin concentrations resulting mainly
from increased insulin production, which is necessary to com-
pensate for resistance to insulin’s actions in hepatic, adipose,
and muscle tissues. Insulin resistance is associated with excess
body weight, physical inactivity, aging, inflammation, type 2
diabetes mellitus, and cardiovascular disease [69].
The fact that responsiveness to insulin is affected by several
processes such as lipid accumulation, reactive oxygen species
production, inflammation, ER stress, and mitochondrial turn-
over, suggest a relationship between insulin response and
autophagy pathway. During nutrient deprivation, glucagon
causes upregulation of autophagy, whereas excess nutrient
supply leads to downregulation of autophagy through insulin
signaling [14]. Furthermore, hyperinsulinemic, high fat diet-
fed mice [17], as well as obese (ob/ob) mice [18], display
impaired hepatic autophagy, as indicated by low levels of
LC3II and high levels of p62 (a protein normally degraded
via autophagy). Of note, decreased autophagy in ob/ob mice
was associated with decreased insulin signaling and increased
ER stress, both of which were rescued by Atg7 overexpres-
sion [16]. Furthermore, studies in mice with selective defi-
ciency of autophagy in β-cells demonstrated reduced conver-
sion of LC3I to LC3II, marked accumulation of p62, and large
protein aggregates in the cytosol of those cells. Importantly,
reductions in basal autophagy levels allowed intracellular
accumulation of damaged organelles, particularly dysfunc-
tional mitochondria, that promoted increases in reactive oxy-
gen species and reductions in glucose-stimulated insulin se-
cretion in these mice [70, 71], who additionally developed
diabetes with markedβ-cell loss when fed a high-fat diet [72].
Considering that hyperinsulinemic states decreases autoph-
agy, and that decreased autophagy can, in turn, downregulate
insulin signaling, it is clear that autophagy and insulin signal-
ing participate in a feedback mechanism with reciprocal reg-
ulation. The molecular basis for this reciprocity is via insulin
signaling-mediated activation of mTORC1 during adequate
substrate availability and mTORC1 inhibition of insulin sig-
naling during decreased substrate availability [25, 28]. Al-
though autophagy also may protect β-cell function [73], ac-
celerated autophagy also appears to be involved in β-cell
death under special conditions [67].
7 Potential targets in the autophagic machinery
Most of the results previously discussed suggest that regula-
tion of autophagy could be a useful target to prevent or control
some of the metabolic abnormalities associated with
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cardiovascular disease or atherosclerosis itself (Table 1). For
example, experimental studies have shown that blocking path-
ways that stimulate autophagy, particularly in adipose tissue,
may reduce WAT and increase β-oxidation; which in turn
would decrease obesity and the associated metabolic disor-
ders. It is important to highlight that any attempt to inhibit
autophagy to prevent or treat obesity must first address im-
portant questions as to how such inhibition might affect
mitophagy (process to remove damaged mitochondria
through autophagy) in mature adipose tissue, as well as what
would be the systemic effects of this inhibition [9, 74]. Eluci-
dating the answers to these questions could provide the basis
for novel approaches to converting WAT to BAT and effec-
tively treating obesity and its associated metabolic disorders
[43]. Conversely, activators of autophagy such as rapamycin
and its analogs, everolimus and sirolimus, which act via
mTOR inhibition, have shown promise, in preclinical studies,
as beneficial potential therapeutics for coronary heart disease.
These mTOR inhibitors, routinely used in drug eluting stents,
were found to prevent atherosclerosis development and pro-
gression in atherogenic mouse models [75, 76], as well as
specifically reduce the cholesterol content of the aortic arch
[77]. Furthermore, a selective clearance of lesional macro-
phages and rise in apolipoprotein A1 and HDL were observed
after rapamycin or sirolimus treatment, which suggests anoth-
er plausible mechanism by which mTOR inhibition exerts
atheroprotective effects [78, 79]. Although pharmacological
inhibition of mTOR can increase plasma levels of LDL-
cholesterol and triglycerides [80], as well as proinflammatory
cytokines such as interleukin-6, monocyte chemoattractant pro-
tein-1, and tumor necrosis factor-α [81], combined treatment
with lipid-lowering therapy or anti-inflammatory agents, may
help to prevent the adverse effects of drug-induced autophagy
without affecting the ability of these agents to deplete lipids and
reduce macrophages with in atherosclerotic plaques [80, 81].
8 Conclusions
Autophagy is primarily a protective process that plays a role in
recycling cellular constituents and maintaining cell homeosta-
sis. Based on the literature reviewed here-in, it appears possi-
ble that reducing autophagy in adipose tissue might be an
approach to controlling obesity whereas increasing autophagy
in the liver, β cell, or atherosclerotic lesion might provide
protection from hyperlipidemia, diabetes mellitus, and coro-
nary events secondary to rupture of necrotic atherosclerotic
plaques. However, developing tissue specific approaches with
narrow therapeutic benefit:risk ratios will be very challenging.
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